The recommendations contained in this guideline are a consensus of the Alberta Provincial Breast Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.
The National Guidelines Clearinghouse and SAGE Directory of Cancer Guidelines were also searched from 2006 to June 15, 2012 for guidelines on breast reconstruction. The search returned 17 guidelines, of which seven were relevant. The guidelines, plus an additional guideline from PubMED, were included in the literature review. None of these published guidelines focused specifically and solely on breast reconstruction.
TARGET POPULATION
The recommendations contained in this guideline apply to women over the age of 18 years, who are candidates for mastectomy, either for the treatment of breast cancer or for the prophylaxis of breast cancer in patients at high genetic risk.
RECOMMENDATIONS
1. Eligibility for post-mastectomy breast reconstruction. Patients who are to undergo either prophylactic or therapeutic mastectomy should have access to breast reconstruction consultation.
Various patient and treatment factors affect options, risks, and outcomes of a woman's breast reconstruction. Consultation with a specialist in breast reconstruction can provide a patient with a specialized treatment plan and anticipated outcomes so she can determine if breast reconstruction is appropriate for her. Table 1 presents factors which may limit options and outcomes of breast reconstruction.
Types of breast reconstruction.
• Several types of breast reconstruction are available, including: implant-based, autologous flap (i.e., DIEP, TRAM, SIEA), and combination reconstructions (i.e., LD with implant).
• There is no evidence to suggest that one type of procedure can be recommended over another.
The decision as to which type of reconstruction to use should be left to the discretion of the surgeons and the patient after providing counseling on the benefits and limitations of each procedure. Table 1 presents factors which may influence the type of reconstruction to be performed.
• Patients for whom radiotherapy is planned or highly likely should be discussed for breast reconstruction appropriateness in a multidisciplinary setting; in general, reconstruction should be delayed until after treatment with radiotherapy has been completed.
 In patients where the likelihood of radiotherapy after mastectomy is uncertain (e.g., clinically staged node negative T1 or T2 tumors), an "upfront" staging sentinel lymph node biopsy (SLNB) could be considered as a separate, outpatient procedure to assist in determining the probability of post-mastectomy radiotherapy prior to proceeding with mastectomy and immediate reconstruction.  Data on the benefits and limitations of an "upfront" SLNB is limited to retrospective case series only. Until randomized data is available to compare "upfront" staging with intraoperative staging using frozen section analysis, one strategy cannot be recommended over another.
• Patients receiving other therapies, including chemotherapy, can be safely offered breast reconstruction with no evidence of adverse effects on the outcome of reconstruction and no clinically relevant delay in chemotherapy or adverse effect on the efficacy of chemotherapy.
• Patients for whom immediate breast reconstruction is not appropriate may be considered for delayed breast reconstruction as an acceptable alternative. 4 . Factors that can affect the outcomes of breast reconstruction ( Table 1) . Factors that should be weighed when considering candidates for any breast reconstruction (immediate or delayed) include:
• treatment factors: prior, concurrent, or known future breast cancer treatment;
• patient factors: co-morbidities, body habitus, smoking status, behavioral/ lifestyle factors; and
• cancer factors: tumour stage and location, risk of relapse. 5 . Extent of mastectomy (i.e., skin-sparing, nipple-sparing).
• Skin-sparing mastectomy is acceptable for any patient undergoing immediate breast reconstruction.
• Nipple-sparing mastectomy is generally not recommended for patients with malignancy. The decision as to whether to pursue a nipple-sparing procedure requires multidisciplinary input and discussion between the surgeons and the patient about potential additional risks associated with this approach.
• There is limited evidence around what surgical factors to consider when performing mastectomy; however, based on consensus of the guideline working group, a list of technical considerations is included in Appendix A.
Risks and benefits of breast reconstruction.
• Patients should be made aware that breast reconstruction is a complex, major, multi-step surgery and that complications can occur with any reconstruction.
• Patient expectations should be assessed prior to surgery, in order to optimize care. In addition, patients should be made aware that cosmetic results may vary from patient to patient and that the reconstructive surgery will not restore the breast to its original appearance.
Post-breast reconstruction surveillance.
There is no evidence to support routine screening mammography of the reconstructed breast, in the absence of a palpable recurrence or symptoms of recurrence. Fat necrosis is a common and benign mammographic finding in patients with reconstructed breasts. Patients with suspicious masses or symptoms should be referred to a surgeon for examination and further workup.
8. Implant-based acellular dermal matrix reconstructions.
• The use of Human Acellular Dermal Matrix (HADM) in immediate prosthetic breast reconstruction confers the potential benefits of improved aesthetic results, reduced rates of capsular contracture and implant malposition, and the possibility of a single-stage "direct to implant" procedure for carefully selected patients.
• These benefits should be weighed against the potentially higher risks of postoperative seroma, infection, and mastectomy skin flap necrosis in HADM-assisted prosthetic reconstruction, when compared to traditional, non HADM-assisted techniques.
• Based on consensus, the use of HADM in breast reconstruction should be at the discretion of the reconstructive surgeon, in consultation with the patient and oncologic team. Indications to use HADM include two-stage expander implant reconstruction or direct to implant single-stage reconstruction, to gain increased control over infra-and lateral mammary fold position and ptosis.
Adjunctive autologous fat grafting (lipofilling) for contour regularities after breast reconstruction.
There is currently limited data on the long-term oncologic safety and long-term contour benefits of lipofilling. Data from comparative studies and case reports suggest that patient satisfaction is good; however more data is needed.
TREATMENT ALGORITHM
An algorithm for the use of breast reconstruction in patients undergoing mastectomy is presented in Figure 1 . This algorithm was made in an effort to standardize clinical practice across the province. The information is not meant to be prescriptive or to replace the clinical judgment of any medical practitioner. 
DISCUSSION

Rationale for Breast Reconstruction
Therapeutic reasons for mastectomy often include lack of response or tumour progression following chemotherapy, multicentric tumors, contraindications to radiotherapy, local recurrence following breast conserving surgery, inflammatory breast cancer, and breast cancer during pregnancy if radiation therapy cannot be delayed until the postpartum period. 1 Despite equivalence, some women choose mastectomy out of fear of cancer. Although prophylactic mastectomy to the contralateral breast is not typically encouraged in patients with a known sporadic ipsilateral breast cancer treated with mastectomy, women often opt for this procedure out of fear of cancer. 1 In patients undergoing reconstructive breast surgery, an evaluation of psychological morbidity showed that recalled distress about mastectomy was lower among those who had reconstruction immediately (i.e., at the time of mastectomy) or early (i.e., within one year), whereas those who had delayed reconstruction (i.e., more than one year later) had significantly more recalled distress about mastectomy. 14 Similarly, a comparison between immediate (n=25) and delayed (n=38) breast reconstruction, using a standardized symptom inventory (BSI) and a self-report questionnaire, revealed that only 25% of the women who underwent immediate reconstruction reported "high distress" about mastectomy, versus 60% of the delayed reconstruction group (p=0.02). Ninety-six percent of the immediate group and 89% of the delayed group reported satisfaction with results. 15 A comparison of psychological outcome and satisfaction among patients who underwent wide local excision with radiation (n=254), mastectomy alone (n=202), or mastectomy with breast reconstruction (n=121) revealed significant differences between the three groups, in terms of satisfaction and psychosocial morbidity (i.e., anxiety, depression, body image, sexuality and self-esteem). Psychosocial morbidity was lowest in the wide local excision group, followed by the breast reconstruction group, with the highest morbidity observed in the mastectomy alone group. 16 Beyond the first year after diagnosis, a woman's quality of life is more likely influenced by her age or exposure to adjuvant therapy than by her breast surgery. 17, 18 Metcalfe, et al. recently reported data on 190 women, which showed that women undergoing delayed breast reconstruction (i.e., already had a mastectomy) had higher levels of body stigma (p=0.01), body concerns (p=0.002), and transparency (p=0.002) than women undergoing mastectomy alone or mastectomy with immediate reconstruction. However, by 1-year follow-up, there were no significant differences in any of the psychosocial functioning scores between the groups. 9 It should be noted, however, that there are inconsistencies in the methods used among studies, the types and definitions of complications reported among studies, and the populations who self-select to undergo each procedure due to aesthetic goals or age. 19 Moreover, the characteristics of patients who undergo reconstruction may be different than those who do not; several analyses of the Surveillance, Epidemiology, and End Results (SEER) database describe factors that are significantly associated with a lower rate of reconstruction among breast cancer patients, including African American race or other minority races (versus Caucasian), nonmetropolitan dwelling (versus metropolitan), receipt of radiation therapy, older age, married (versus never married or widowed), and unilateral mastectomy (versus prophylactic mastectomy of contralateral breast). [20] [21] [22] [23] Another challenge in interpreting satisfaction data is that validated specific questionnaires for breast reconstruction have not yet been developed. 24 Other reasons for not undergoing reconstruction many include the presence of comorbidities or patient preference. 25 Patient preference may also influence whether a patient undergoes immediate or delayed breast reconstruction. 26 Nevertheless, the option to undergo breast reconstruction should be discussed with patients who are candidates for mastectomy.
Despite the evidence for positive outcomes associated with reconstruction, the rate of its use may be low. Not all women choose to undergo reconstruction; choosing not to undergo breast reconstruction alleviates the risks associated with breast reconstruction. 9, 17, 26 Uptake of breast reconstruction may also be due to access issues. The most recent Canadian population-based data, taken from the 1980s and 1990s suggested a rate of approximately 4 to 8%, while in the US the rate ranged from approximately 8 to 17% for that same time period. 27 There were, however, local rate variations at that time; the Calgary rate was reported to be approximately 15%, 28 while the rates in Toronto and urban Nova Scotia were 10% and 4.8%, respectively. 27 More recent US population-based data has shown a rate of 25 to 30%. 27 The need for radiotherapy complicates breast reconstruction following mastectomy, due to increased risk of capsular contracture, flap fibrosis, need for additional surgery, risk of infection, etc.). As such, there continues to be much debate regarding the timing of mastectomy in patients requiring radiotherapy. Adjuvant radiotherapy is recommended for patients who undergo mastectomy for the management of T1/T2 node positive breast cancer, T3/T4 breast cancer. Radiation may be offered to women with neoadjuvant chemotherapy in clinical stage II and is recommended in clinical stage III. 29, 30 Besides the cancer-related factors described above, physician knowledge and attitudes, as well as practice setting, also influence the rate of reconstruction. 27 The types of breast reconstruction procedures that are currently available for patients vary by several factors, including timing of the procedure (i.e., immediate versus delayed reconstruction), the amount of skin preserved at the time of mastectomy and type of reconstruction used (i.e., prosthetic implant versus autologous tissue implant). The role of new products, such as acellular dermal matrix, further complicates surgical decision making.
Breast reconstruction following mastectomy is oncologically safe. A recent meta-analysis found that the risk of breast cancer recurrence among patients with breast cancer who underwent mastectomy and immediate breast reconstruction was equivalent to those who underwent mastectomy alone (odds ratio, 0.98; 95% CI 0.62-1.54). 31 Furthermore, breast reconstruction can achieve a high level of satisfaction and better psychosocial outcomes for patients. [32] [33] [34] Despite the value of breast reconstruction, there is some uncertainty around aspects of the procedure, such as timing of reconstruction relative to adjuvant therapy, extent of mastectomy, type of reconstruction, and patient selection criteria. This guideline was developed to provide recommendations on these topics, for use by general and plastic surgeons in Alberta. To complement the following discussion, a complete summary of the evidence is provided in table form in Appendix B.
Methods of Reconstruction
Prosthetic implants and autologous tissue are available for breast reconstruction procedures. No randomized controlled trials have been performed to compare these two types of reconstructions in terms of cosmesis, complications, and oncologic safety in patients with breast cancer. Furthermore, the few observational studies available in the literature have used varying, non-standardized measures to assess aesthetic outcomes; 35, 36 factors such as cost, 37 pain, 38 aesthetics, [39] [40] [41] feasibility with radiotherapy, 42, 43 and complication rates 24, [44] [45] [46] have been used to rank one reconstructive procedure over another.
Recently developed patient-rated outcome measures, such as the BREAST-Q 47 and the BRECON 35 will significantly clarify these issues in future comparative studies.
Patient Satisfaction
Recently, patients who had completed alloplastic reconstruction at least one year prior were surveyed using two questionnaires (i.e., the BREAST-Q and the EORTC QLQC30 [Br23]) to compared satisfaction among silicone (n=75) and saline (n=68) implant recipients (response rate: 58%). Using the BREAST-Q, silicone implant recipients had significantly higher scores on overall satisfaction (p=0.008), psychological well-being (p=0.032), sexual well-being (p=0.05), and satisfaction with surgeon (p=0.019). Using the EORTC QLQC30 (Br23), silicone implant recipients had significantly higher overall physical function, and significantly lower systemic side effects. 48 The Michigan Breast Reconstruction Outcomes Study, a prospective cohort study, looked at patient satisfaction at two years following reconstruction with either flaps (pedicle and free TRAM) or with expanders / implants; aesthetic satisfaction was nearly three-fold higher among patients who underwent flap reconstruction (OR 2.8, p<.01), but there was no difference between these groups in terms of general satisfaction. 49 A survey among women (n=33) who had undergone postmastectomy breast reconstruction sought to compare the transverse rectus abdominis musculocutaneous (TRAM) flap with implant reconstruction. Among those who agreed to participate, 23 completed a self-assessment questionnaire on quality of life, psychological symptoms, functional status, body image, and global satisfaction. Patients who had undergone TRAM flap reconstruction were significantly more satisfied with how their recon-structed breast felt to the touch (p=.01); however, patients with TRAM flap reconstruction identified more difficulties, as far as functioning at work or school, performing vigorous physical activities, participating in community or religious activities, visiting with relatives, and interacting with male friends (p<.04). 50 A cross-sectional study among 482 women who underwent mastectomy followed by implant-based reconstruction were surveyed using the Breast-Q tool to assess satisfaction with their procedure; silicone was used in 176 women while saline was used in 306 women. Patient satisfaction was significantly higher in those with silicone implants (p=.016); however, postmastectomy radiotherapy had a significant negative effect on satisfaction (p<.000) in both silicone and saline recipients and in both groups, satisfaction diminished over time (p=.017). 51 A retrospective study among all patients undergoing immediate breast reconstruction (n=186) at a single institution, over a five-year period revealed a lower complication rate for patients with expander/implant reconstructions (21.7%), than those with latissimus flap reconstructions (67.9%) or TRAM flap reconstructions (26.9%). However, patients who underwent TRAM flap reconstruction had the lowest reoperation rates (5.8% versus 11.3% for expander/implant and 10.7% for latissimus flap) and highest aesthetic scores. Patients were asked to rate their satisfaction with the procedure; 42% responded and revealed a higher level of satisfaction (moderate or higher) among patients who underwent expander/ implant reconstruction (93.8% versus 76.9% for latissimus flap and 83.3% for TRAM flap). 52 A prospective cohort comparing implant-assisted latissimus dorsi with tissue-only autologous latissimus dorsi flap reconstruction (N=182) among primary early-stage breast cancer patients demonstrated equivalent short-term (0 to 3 months) and long-term (4 to 12 months) complication rates (respectively: 66% for implant vs. 51% for autologous; p=.062 and 48% for implant vs. 45% for autologous; p=.845). However, role functioning and pain were significantly worse in the tissue-only autologous group (p=.002 for both). Radiotherapy did not affect quality of life in this study. 53 Other data, however, suggests higher patient satisfaction with autologous reconstruction. A retrospective study among all patients undergoing postmastectomy breast reconstruction (n=583), at a single institution, compared patients with tissue expander/implant reconstruction with those who underwent latissimus dorsi, TRAM, and deep inferior epigastric perforator (DIEP) flap reconstructions. When asked questions about their quality of life, 439 patients (75%) responded, indicating that the highest level of general satisfaction was among patients who underwent the DIEP procedure (80%; p<.001), while those who underwent pedicle TRAM had the highest level of aesthetic satisfaction (77%; p<.001). After controlling for healthrelated quality of life and length of time since surgery, autologous reconstruction had significantly higher general and aesthetic satisfaction than implant-based reconstruction (p=.017 and p<.001, respectively).
Abdominal-based flaps were associated with significantly higher general and aesthetic satisfaction than latissimus flaps (p=.011 and p=.016, respectively). 54 A study looking at various forms of breast reconstruction, using the validated BRECON questionnaire showed similar satisfaction across various forms of reconstruction, with the exception that the recovery subscale had lower scores for autologous reconstructions. 55 
Acellular Dermal Matrix (HADM)-Assisted Implant-Based Reconstructions
Over the past decade, human acellular dermal matrices (HADM) have been increasingly utilized to facilitate standard two-stage expander/implant immediate breast reconstructions, as well as emerging, single stage "direct-to-implant" techniques. In a 2010 survey of US Plastic Surgeons, over half reported frequent use of HADMs as an adjunct to implant-based breast reconstruction. 56 HADMs are immunologically inert, processed dermal matrices derived from human cadaveric skin. The product is attached to the inferior border of the released pectoralis major muscle superiorly, and the inframammary fold inferiorly and laterally, thereby forming a "hammock" which covers and supports the expander or implant beneath. 57, 58 Over time, the HADM is revascularized and repopulated by the patient's own cellular elements, forming a soft, elastic, living interface between prosthesis and patient.
Aesthetic advantages of HADM-assisted techniques include better definition and control of the implant pocket, better infra-and lateral mammary fold definition, more natural ptosis, and reduced rates of capsular contracture. 59, 60 A retrospective chart review among patients undergoing implant-based immediate breast reconstruction, either with ADM (n=208) or without (n=129), demonstrated significantly better aesthetic outcomes in the ADM group. In multivariate logistic regression, ADM use was associated with less capsular contracture (OR = 0.18; 95% CI 0.08-0.43) and mechanical shift (OR = 0.23; 95% CI 0.06-0.78). 61 Data from meta-analyses has demonstrated slightly higher rates of seroma, infection, and flap necrosis for HADM-assisted reconstructions, compared to traditional, non-HADM-assisted techniques. [62] [63] [64] These studies should be interpreted with caution, as they reflect the collective pooling of early results from multiple surgeons' initial experiences with the product. 65 More recent studies have demonstrated that with judicious patient selection and precise intraoperative technique 66, 67 superior aesthetic results can be achieved with a safety profile that is comparable or superior 68 to reported series of traditional, non-HADM assisted approaches. [69] [70] [71] Certain questions surrounding HADM-assisted reconstruction have not yet been definitively answered, in particular whether or not the use of HADM results in reduced postoperative pain, shorter hospital stays, and reduced expander fill times, in comparison to traditional techniques. Although retrospective reviews and studies utilizing pooled results have suggested reduced postoperative pain and time to expansion, a randomized controlled trial of 70 patients failed to demonstrate significant differences in postoperative pain (p=0.19), pain during expansion (p=0.65), postoperative narcotic use (p=0.38), nor rate of expansion (p=0.83) for HADM-assisted techniques. 72 A matched cohort study yielded similar findings. 73 A multicenter prospective cohort evaluating HADM-assisted immediate expander-based breast reconstruction reported an overall complication rate of 4.6% (3 of 65 breasts), consisting of one case of cellulitis and two cases of partial mastectomy flap necrosis that required debridement, with no seromas or explantations. 74 Current data is also insufficient to draw definitive conclusions regarding the overall cost-effectiveness of HADM in breast reconstruction. A recent Canadian cost analysis study demonstrated that although these products are expensive, their use can result in an overall cost savings to the health care system as a result of fewer revisionary and second stage procedures. 75 The authors emphasize the need for further randomized controlled trials to evaluate both the clinical outcomes and costs of ADM-assisted breast reconstruction. One such multicentre Canadian trial (NCT00956384) comparing HADM-assisted single stage, "direct-to-implant" reconstruction to conventional two-stage expander implant reconstruction, is currently underway. Outcomes measures include aesthetic outcomes, short and long term complications, and overall patient satisfaction. This trial should clarify the role of HADM in "direct-to-implant" reconstructions, and will also examine the cost-effectiveness of the procedure. 76 Currently, the majority of evidence surrounding the adjunctive use of HADM in implant based breast reconstruction is retrospective. 77 Until higher level prospective evidence is available to provide more specific guidelines to clinical practice, the consensus of the guideline working group is that while sufficient evidence exists to support the use of acellular dermal matrices in breast reconstruction, the specific applications for its use are most appropriately left to the discretion of the surgeon, in consultation with the patient and oncologic team. Attempting any immediate device-based reconstruction (i.e., single stage or two stage) is much more likely to achieve an aesthetically acceptable, satisfactory result with ADM, as compared to using a traditional two stage expander implant sequence. 78
Autologous Fat Grafting (Lipofilling)
As an adjunct to primary breast reconstruction, adipose tissue can be harvested and refined and then injected in small aliquots into the reconstructed breast, theoretically providing better structure and contour than could be achieved with breast implants alone. There is currently no data from clinical trials or metaanalyses looking at autologous fat grafting (lipofilling). There is only limited data on the long-term oncologic safety and prosthetic durability of lipofilling. 79 In terms of patient satisfaction, an observational study among patients undergoing nipple-sparing, skin-sparing and skin-reducing mastectomies and not requiring adjuvant radiotherapy (n=20) employed the use of autologous fat injection secondary to breast reconstruction and found that both patient-reported and surgeon-reported esthetic satisfaction was high, and well-correlated. 80 Data from a prospective series of 68 breast cancer patients, who had had mastectomy and irradiation and then underwent one or more (mean 2.3, range 1-6) fat grafting sessions prior to breast implant reconstruction indicated that cosmesis was good (mean score 4.5 of 5). However, more importantly from an oncologic safety perspective, after a mean follow-up of 23 months, there were no local recurrences. 81 Likewise, a retrospective review, comparing the use of breast reconstruction with fat grafting versus reconstruction without fat grafting, among patients undergoing mastectomy with immediate tissue expander (n=886), showed that after a mean follow-up of 44 and 42 months respectively, showed that fat grafting did not affect local tumor recurrence or survival. 82
Fat graft retention has been reported as being good. 83 The most common complications with autologous fat grafting include fat necrosis (3.6%), oil cysts (1.8%), and infection (0.9%), according to a retrospective review of patients (n=49) who underwent fat grafting to reconstructed breasts. 84,85 Complications appear to be higher with implant-based reconstructions as compared to autologous flap reconstructions. 86 While data from comparative studies and case reports suggest that complications are minimal and show good patient satisfaction, more data (specifically from randomized controlled trials) is needed. 89 It has been reported elsewhere, however, that the cost of a latissimus dorsi, TRAM, or DIEP flap reconstructions, including both primary surgery and any revisions, are similar, and that any small financial benefits gained from the implant reconstruction at initial surgery will be lost over time, as patients require additional revisions. 90 As such, no recommendations can be made, favoring one type of reconstruction over another from a cost perspective. The decision to use an implant or an autologous flap, or to use a latissimus dorsi or TRAM or DIEP flap should be left to the discretion of the plastic surgeon and the patient after counseling the patient on the benefits and limitations of each type of available reconstruction.
Timing of Reconstruction
Immediate breast reconstruction (i.e., at the time of mastectomy) has been a topic of increased discussion in recent years; however, the use of this combined surgical approach has been around for quite some time. In 1983, Dean, et al. conducted a randomized controlled trial in which patients underwent either immediate breast reconstruction or were offered reconstruction twelve months later. Immediate reconstruction reduced the psychiatric morbidity assessed three months after operation; women who underwent reconstruction were found to have more "freedom of dress" and were less likely to be "repulsed by their own naked appearance" than women who did not undergo reconstruction. 91 Since then, further evidence on the psychosocial benefits of immediate reconstruction has surfaced. A cross-sectional study, comparing immediate and delayed reconstruction with mastectomy alone, among patients with breast cancer (n=190) found significantly higher levels of body stigma and body concerns among patients in the delayed reconstruction group. 9 A recent Cochrane review showed support for the benefits of immediate versus delayed reconstruction, although there was only one randomized controlled trial with some flaws in terms of bias and outcome reporting, that immediate reconstruction reduced psychiatric morbidity at three months postoperatively, as compared with delayed or no reconstruction. 92 Heterogeneity exists between studies in the evaluation of cosmesis and complications between immediate and delayed reconstruction, which needs to be considered when interpreting results. 19, 93 Regarding safety, a prospective cohort of patients with T1-T3 tumours (n=677) underwent either mastectomy alone, or mastectomy with immediate breast reconstruction; no radiotherapy was given to any patients. After a median follow up of 70 months (range 13-114 months), the local recurrence rate was 5.2% for immediate reconstruction group and 9.4% for mastectomy only group. The regional and distant metastases rates did not differ either (1.4% versus 1.3% and 13.9% versus 16.4%, respectively). There was also no difference between the groups in terms of overall survival (hazard ratio, 1.03) or disease-free survival (hazard ratio, 0.99). 94 Furthermore, the meta-analysis by Gieni, et al. found no differences, in terms of the risk of recurrence between patients who underwent immediate reconstruction and those who underwent mastectomy alone. 28 Guidelines on this issue generally indicate that immediate reconstruction is equally as safe, oncologically, as delayed reconstruction and offers patients an improved psychological profile; as such, there is no psychological or oncologic basis for waiting to perform reconstruction, in patients who meet the selection criteria for reconstruction. [95] [96] [97] [98] [99] [100] [101] Based on the evidence available, immediate breast reconstruction should be considered, whenever possible, for any patient who is a candidate for breast reconstruction.
Timing of Reconstruction in the Setting of Adjuvant Radiotherapy
Most guidelines that address the timing of adjuvant radiotherapy recommend that breast reconstruction be delayed or at least discussed in a multidisciplinary setting, in patients with breast cancer for whom radiotherapy is planned. 95, 96, 102 The NCCN breast cancer guideline (v.1.2012) states that radiotherapy should be completed first, when an autologous reconstruction is planned; furthermore, an expander/implant reconstruction can be done immediately, but carries a significantly increased risk of implant capsular contracture. Furthermore, in patients who have previously received radiotherapy, expander/implant reconstruction carries higher risk. 103 A retrospective chart review comparing radiotherapy before delayed TRAM flap reconstruction with immediate TRAM flap reconstruction followed by radiotherapy (mean radiotherapy dose: 50-51 Gy) among 102 patients with breast cancer found that the rate of late complications was significantly higher among patients in the immediate reconstruction group (87.5% vs. 8.6%; p=0.000); furthermore, the need for an additional flap to correct the distorted contour from flap contraction was observed among nine patients (28%) in the immediate reconstruction group. 104 In patients who underwent TRAM reconstruction (n=680), those who received pre-operative radiotherapy were found to have higher rates of fat necrosis (>10% of total reconstruction; 17.6% versus 10.1%, p=.032). Obesity and radiotherapy were also both found to be associated with fat necrosis and major infection in logistic regression analyses. 105 Similarly, a systematic review, including four studies, that compared the outcomes of patients in terms of the timing of radiotherapy with autologous reconstruction, found that the overall incidence of complications was increased in patients who received radiotherapy in three of four studies. 106 A more recent meta-analysis of postoperative morbidity following immediate or delayed breast reconstruction (n=1,105) found that patients undergoing radiotherapy were more likely than patients not receiving radiotherapy to suffer morbidity (odds ratio, 4.2; 95% CI 2.4-7.2) but that autologous reconstruction was associated with less morbidity than implant-based reconstruction (odds ratio, 0.21; 95% CI 0.1-0.4). Overall, this study found that delaying reconstruction until after radiotherapy had no significant effect on outcome (odds ratio, 0.87; 95% CI 0.47-1.62). 107 Among patients undergoing reconstruction with implants, a retrospective chart review compared those with irradiated implants (average 50 Gy) with those with nonirradiated implants, all placed submuscularly or beneath a flap (n=297), and found that complications (i.e., capsular contracture, pain, exposure, and implant removal) were significantly more frequent in patients with implants who received radiotherapy. 108 In patients who are likely to receive radiotherapy, a delayed-immediate reconstruction (i.e., expanders are placed at mastectomy) may be preferred, as it is thought to avoid difficulties associated with radiotherapy delivery after immediate reconstruction and preserves the opportunity for the aesthetic benefits of skin-sparing mastectomy. 109 However, in a prospective study comparing timing of radiotherapy on permanent implants versus on the tissue expanders (all two-stage immediate with subpectoral temporary expanders and permanent implants), the rate of failure (i.e., removal of the implant, leaving the chest wall flat, or change to a flap-based technique) was significantly higher when radiotherapy was delivered at the tissue expander stage rather than at the permanent implant stage(40% versus 6.4%; p<.0001). The capsular contracture rate was similar for both groups. 110 Where feasible, another approach may be to consider an upfront "staging" sentinel lymph node biopsy, as a reliable means of determining the probability of post-mastectomy radiotherapy in clinically node negative patients. McGuire, et. al. suggest that SLNB be performed as a separate outpatient procedure several days prior to mastectomy when immediate reconstruction is planned. The authors acknowledge the drawbacks of a separate procedure, but argue that this strategy can allow SLNB to be performed with minimal morbidity with monitored anesthesia care and local anesthesia, and can eliminate the need for frozen section diagnosis. 111 Several retrospective reviews have presented data to support this strategy, citing the following reasons for performing an upfront SLNB: to avoid the unreliability of frozen section diagnosis as compared to permanent results, 112 to avoid the high rate of complications and implant loss among patients undergoing post-mastectomy radiotherapy, 113,114 and to identify patients for whom delayed reconstruction is preferred due to a positive SLNB finding. 115 Those against this strategy have provided retrospective data to suggest that that the false negative rate when performing SLNB at the time of mastectomy and immediate reconstruction is low (7.8%) and that the touch preparation analysis from the SLNB changes the plan in only a small number of patients (2.1%). 116 Rationale for not performing an upfront SLNB include additional expense, increased delay in initiation of systemic therapy, and the propensity of procedure-related morbidity. 116,117 Data on the feasibility of intraoperative SLNB diagnosis suggests that this strategy is practical. 118,119 Nevertheless, no randomized controlled trials have been conducted to compare upfront staging with intraoperative staging in the setting of immediate reconstruction. Therefore, a recommendation cannot be made for or against either strategy.
Impact of Chemotherapy on Reconstruction
Data suggest that immediate reconstruction can be safely integrated with chemotherapy, without a significant impact on complications. A prospective randomized trial comparing immediate modified radical mastectomy against initial systemic therapy followed by mastectomy found that there was no significant difference in the risk of complications and that immediate breast reconstruction was not an independent predictor of complications. 120 A retrospective series of patients receiving neo-adjuvant chemotherapy for breast cancer, followed by surgery (N=2,004; American College of Surgeons National Surgical Quality Improvement Program database), looked at factors affecting post-operative complications. Wound complications occurred in 3.1% of patients. There was a trend towards increased complications in neoadjuvant patients undergoing mastectomy with immediate reconstruction (OR, 1.58; 95% CI, 0.98-2.58). 121 Most prospective and retrospective series have reported similar results. 122- 130 One study reported greater implant infection rates 130 with chemotherapy and one reported a higher rate of expander removal with chemotherapy. 127 Understandably, some practitioners prefer a delayed breast reconstruction approach in patients deemed to have a high risk of local recurrence clinically (in the short term setting) or if radiotherapy is required; the need for chemotherapy, however, should not preclude an immediate reconstruction in this patient population.
Data suggest that reconstruction may impact the time to chemotherapy, but not necessarily in a clinically significant manner. A retrospective comparative study analyzed data from patients undergoing mastectomy with and without free flap IBR, followed by adjuvant treatment (N=166) and found that the mean time period between surgery and commencement of adjuvant treatment was 15 days longer in the immediate reconstruction group. Delays were related to surgical complications. 131 A prospective series of 391 consecutive women who underwent mastectomy (n=243) or mastectomy and immediate reconstruction (n=148) showed a statistically significant, difference in the median time to chemotherapy (6.8 weeks for mastectomy alone vs. 8.5 weeks for immediate reconstruction; p=0.01). 124 A delay of approximately one to two weeks to chemotherapy is not likely to impact clinical outcomes, provided thwe patient is ready to start chemotherapy within 12 weeks; however, the decision whether to perform an immediate reconstruction should be weighed against this potential delay.
Extent of Mastectomy
In a meta-analysis of nine studies with data for over 3,700 patients, skin-sparing mastectomy with immediate reconstruction has been found to be equivalent to conventional mastectomy without reconstruction in terms of oncologic safety; the local recurrence rate was 6.2% for skin-sparing mastectomy and 4.0% for conventional mastectomy (odds ratio, 1.25; 95% CI 0.81-1.94), while the distant relapse rate was 10.0% for skin-sparing mastectomy and 12.7% for conventional mastectomy (odds ratio, 0.67, 95% CI: 0.48-0.94). 132 A prospectively maintained database of patients (n=428) undergoing nipplesparing mastectomy with immediate breast reconstruction for in situ cancer (16.9%), invasive cancer (45.8%), or prophylactic risk-reduction (37.3%) revealed a locoregional recurrence rate of 2% overall (median follow-up 28 months) and 2.4% among those with at least 3 years' follow-up (median follow-up 45 months). Nipple tissue contained in situ cancer in 11 breasts (1.7%) and invasive cancer in 9 breasts (1.4%) and these were managed with repeat excision (7 cases), NAC removal (9 cases), or radiotherapy without further excision (4 cases); there were no recurrences in the nipple-areolar complex. 133 In line with these findings, current published guidelines recommend skin-sparing mastectomy as an acceptable approach. 95, 96, 103 Nevertheless, skin-sparing mastectomy may be underutilized. A postal survey administered to general surgeons who perform breast cancer surgery found that most (89%; 331 of 370) perform mastectomy for cancer with planned immediate reconstruction. Ninety percent felt that skinsparing mastectomy did not result in higher rates of local recurrence and 70% felt that cosmesis was superior with immediate reconstruction after skin-sparing mastectomy; yet, only 61% reported that they perform skin-sparing mastectomy in most cases when immediate reconstruction is planned. 134 Nipple-sparing mastectomy is performed in the setting of immediate reconstruction and can achieve good cosmetic results. 135 A prospective study was conducted among patients with no disease within 2 cm of the nipple (n=43), for the purpose of either prophylaxis (n=29) or therapy (n=35: 24 invasive and 11 ductal carcinoma in situ). Patients underwent total skin-sparing mastectomy with preservation of the nippleareola complex, followed by immediate expander/implant-based reconstruction; survival of the nippleareola complex was complete in 80% (n=51) and partial in 16% (n=10) of patients and was highest (97%) with radial incision (n=34). Complications included implant loss, total skin flap necrosis, and infection, but there were no recurrences. 136 Viability of the nipple-areolar complex may be improved by performing a surgical "delay" procedure 1-2 weeks prior to mastectomy, in conjunction with biopsy of the retroareolar tissue. 137 A retrospective chart review of nipple-sparing mastectomy (45 prophylactic and 53 therapeutic), among patients with tumours ≤3 cm in size and ≥2 cm from the nipple, no clinical invasion of the nippleareola, no multicentric disease, negative intra-operative retroareolar frozen section, and no nodal disease, reported no local or regional recurrences in any patients, with a median follow-up of 22.5 months. 138 Despite these and other studies 139, 140 reporting promising results with nipple-sparing mastectomy, there is currently no published data from a randomized controlled trial, on the oncologic safety of nipple-sparing, as compared to conventional skin-sparing mastectomy. Therefore, nipple-sparing mastectomy is generally not recommended for patients with malignancy 95, 96, 103 but could be considered for carefully selected patients, and in patients undergoing prophylactic mastectomy, when done in conjunction with a separate biopsy of the ductal tissue directly underlying the nipple-areola complex. The decision as to whether to pursue a nipple-sparing procedure requires multidisciplinary input and careful discussion with the patient about potential additional risks associated with this approach.
Patient Selection
Several patient factors should be considered when selecting appropriate candidates for breast reconstruction. A recent systematic review on mastectomy complications found that previous breast biopsy or operation and preoperative chemoradiation were significant factors associated with surgical site infection, whereas immediate reconstruction, axillary lymph node dissection, and preoperative chemotherapy were not. 141 Among patients undergoing immediate breast reconstruction, a prospective study demonstrated a significantly greater risk of failure, as revealed by multiple logistic regression analysis, among patients with larger tumours (T3/T4), patients who smoke, and patients with positive nodes. The rate of failure (i.e., the need for a second intervention consisting of ablation or replacement of the prosthesis) was 7% for patients with none of these factors, 15.7% for patients with one of these factors, 48.3% for patients with two of these factors, and 100% for patients with all three of these factors, accurately predicting 80% of failures. 103 A follow-up survey of mastectomy-treated breast cancer patients (N=374; SEER database) five years after treatment suggested that the receipt of reconstruction did not vary by body mass index (BMI): 53% BMI <25 kg/m; 48% BMI 25-30 kg/m; 45% BMI >30 kg/m; p=.43). However, reconstruction type did vary by BMI: TRAM flaps were performed in 53% of patients with BMI >30 kg/m versus 26% of patients with B<I <25 kg/m (p=.01). Patient satisfaction with surgical decisionmaking and surgical outcomes was similar across body mass index categories. 142 Guidelines published by both the National Comprehensive Cancer Network (NCCN) 103 and the Massachusetts Board of Registration in Medicine Expert Panel (MBRMEP) 95 list prior cancer therapy (i.e., chemotherapy, radiotherapy), body composition, and smoking status as factors to consider when selecting patients for reconstruction. The NCCN also adds comorbidities and patient concerns as factors to be considered. Other guidelines included in the literature review for this guideline did not specifically identify patient selection criteria. [97] [98] [99] [100] [101] [102] Based on existing evidence and current guidance, it is recommended that the following patient factors be considered when selecting candidates for reconstruction: prior, concurrent, or future cancer treatment, co-morbidities, body habitus, and smoking history and current smoking status.
Risks and Benefits
Patient expectations should be assessed prior to surgery, in order to optimize care. In addition, patients should be made aware that cosmetic results may vary from patient to patient and that the reconstructive surgery may not entirely restore the breast to its original appearance. Systematic measurement and management of patient expectations may improve patient education, shared medical decision-making and patient perception of outcomes. 143 As with any major surgery, complications can occur with breast reconstruction. The most common complications associated with autologous flap reconstructions are flap necrosis (~5% of patients), infections (~5% of patients), and seroma (~4% of patients). 136 Reoperation is often required in patients who develop flap necrosis. 144 Less common complications from autologous breast reconstruction include bruising and bleeding and chronic pain. 144, 145 Deep inferior epigastric perforators (DIEP) flaps have been shown to carry a higher risk of fat necrosis, flap loss, 145 but lower donor-site morbidity (i.e., bulge formation, hernia), 146, 147 as compared to muscle-sparing transverse rectus abdominis myocutaneous (TRAM) flaps.
In patients who undergo implant-based breast reconstruction with human acellular dermal matrix (HADM), the total complication rate is about 15% and the most common complications are mastectomy flap necrosis (~7% of patients), infection (~5% of patients), and seroma (~5% of patients). 145 Mastectomy flap necrosis can necessitate removal of the implants and reoperation. 133 As with autologous reconstruction, implant-based reconstruction may be associated with bruising and bleeding, 133 chronic pain, 144, 145 implant rupture or malposition, 108, 109 and capsular contracture, which more frequently occurs in patients who undergo radiation therapy. 141, 143, 148, 149 There is evidence to suggest that the risk of capsular contracture is lower with the use of textured implants, as compared to smooth implants. 150 In a very small group of patients with implants, anaplastic large cell lymphoma (ALCL) has been observed. By 2007, only six cases of ALCL in the setting of breast implant surgery had been reported. 110, [151] [152] [153] [154] By 2010, a total of 34 unique cases had been identified among an estimated 10 million women with breast implants and the majority of these 34 patients are still alive and well. 155 The United States FDA then conducted an investigation and concluded that: (1) there is a possible association between ALCL and breast implants, adding that although the incidence is low, the occurrence of ALCL in patients with implants may not be a coincidence;
(2) it is not possible to identify a specific type of implant that is associated with a higher or lower risk of ALCL; and (3) the true cause of ALCL in patients with implants is unknown. 156 Subsequently, the American Society of Plastic Surgeons and the American Society for Aesthetic Plastic Surgery issued a statement indicating that ALCL is extremely rare, that the risk of women with implants developing ALCL is extremely low, and that breast implants are safe and effective. 146, 149, 155, 157 
Post-Breast Reconstruction Surveillance
There is no evidence to support routine screening mammography of the reconstructed breast, in the absence of a palpable recurrence or symptoms of recurrence. Imaging records from 227 patients with a history of post-mastectomy breast reconstruction due to cancer showed that among 116 patients (51%) who underwent surveillance mammography of the reconstructed breast, only one recurrent cancer was detected in an autologous tissue flap reconstruction (0.86% detection rate of non-palpable recurrent cancer), with a recall rate of 4%. Among 54 patients (24%) who presented with symptoms relating to the breast reconstructions (most commonly lump or swelling), half were subsequently found to have no significant abnormality and a third (29%) were found to have fat necrosis. Only four recurrences were found. 158 Presently, assessment with ultrasound and mammography can only be supported in symptomatic patients, with surgical referral the most efficient means of obtaining a diagnosis while minimizing unnecessary tests or biopsies. 159 While in theory patients at high risk of recurrence may also benefit from routine mammography of the reconstructed breast, 160 data is needed to support the selection of these patients.
Resource Implications
The recommendations contained in this guideline reflect the best available evidence on post-mastectomy breast reconstruction. In order to make this guideline operational, at minimum, resources are required to coordinate operation room time between the general surgeon and the plastic surgeon. In addition, infrastructure is needed to facilitate multidisciplinary case discussions for patients needing postmastectomy radiotherapy.
Summary
Breast reconstruction should be made available for patients undergoing mastectomy, for prophylaxis or for the treatment of breast cancer. Patient factors, such as prior, concurrent, or future cancer treatment, comorbidities, body habitus, and smoking history and current smoking status should be considered when selecting candidates for breast reconstruction. Immediate breast reconstruction should be considered, whenever possible, for any patient who is a candidate for breast reconstruction. Delayed breast reconstruction is an acceptable alternative when immediate breast reconstruction is not available or inappropriate. The integration of reconstruction and post-mastectomy radiotherapy should be addressed in a multidisciplinary setting. In general, breast reconstruction should be delayed until after treatment with radiotherapy has been completed. The decision as to which type of procedure to use should be left to the discretion of the surgeons and the patient after providing counseling and based on the benefits and limitations of each procedure. Skin-sparing mastectomy for immediate breast reconstruction is a safe and appropriate approach. Nipple-sparing is generally not recommended for patients with malignancy, but could be considered for carefully selected patients, and in patients undergoing prophylactic mastectomy, when done in conjunction with a separate biopsy of the ductal tissue directly underlying the nipple-areola complex. 
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• Present the guideline at the local and provincial tumour team meetings and weekly rounds.
• Post the guideline on the Alberta Health Services website.
• Send an electronic notification of the new guideline to all members of AHS, Cancer Care.
• Publish the guideline in a peer-reviewed journal.
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APPENDIX A: The Mastectomy -Technical Issues Relevant to Reconstruction
Skin-Sparing Mastectomy. A significant learning curve is required in order to produce viable flaps for breast reconstruction. This procedure should be done by should only be performed by experienced practitioners with appropriate training in skin sparing techniques, as it is technically more challenging than a standard total mastectomy. The skin-sparing mastectomy has been one of the greatest advancements in immediate breast reconstruction (IBR) in the last two decades. 161 It is technically more challenging than the traditional modified radical or total mastectomy, requires close coordination between the oncologic and reconstructive surgeons and depends on proper patient selection and meticulous technique.
Mastectomy Flap Necrosis. The success of IBR largely hinges on the health of the mastectomy flaps. Unfortunately, skin flap necrosis is reported in up to 20% of IBR cases [162] [163] [164] and remains the single most common complication of skin sparing mastectomy. Even minor flap edge necrosis can lead to infection, exposure, and loss of an implant-based reconstruction; any necrosis can significantly compromise the final shape of autogenous tissue-based reconstructions. Other technical issues that can make the environment unfavorable for proceeding with IBR include insufficient or inconsistent skin flap thickness, resection of muscle fascia, and disruption of anatomic breast landmarks.
Oncologic Safety. Although oncologic safety trumps reconstructive issues whenever the two are incompatible, both should be equally achievable in properly selected patients referred for IBR; otherwise, if healthy, consistent skin flaps cannot be assured in a given patient due to oncologic issues, the patient should be referred for delayed breast reconstruction instead. All forms of mastectomy leave some degree of residual breast tissue behind. 161 The various mastectomy techniques differ in terms of the amount of microscopic breast tissue left behind in the skin. These small differences have not been shown to impact the local recurrence of breast cancer 162, [165] [166] [167] [168] Breast Boundaries. Ideally, the mastectomy removes the breast gland only. The historical boundaries of mastectomy (i.e., the clavicle, the rectus sheath, the midline of the sternum, and the anterior latissimus border) were derived from a contrast injection study in 1940. 169 These borders significantly overestimate the actual extent of the breast gland. Schwartz 170 in "Principles of Surgery," describes the anatomy of the breast gland more conservatively: The mature breast of the female extends inferiorly from the second or third rib, to the inframmamary fold at approximately the sixth or seventh rib. Transversely, it extends from the lateral border of the sternum to the anterior or mid axillary line.
Each woman has unique breast anatomy; like the reconstruction, the mastectomy should be customized according to a careful preoperative evaluation in the seated or standing position to identify breast boundaries. Dissecting to the clavicle is rarely necessary, leads to superior hollowing, and creates a difficult to hide, telltale sign of mastectomy that will persist even with reconstruction. Dissecting to or beyond the midaxillary line overly lateralizes the reconstruction, thus leading to dissatisfaction regarding lateral breast fullness that interferes with arm movement. Dissecting beyond the medial breast border at the lateral sternum can be particularly problematic for the reconstructive surgeon, as the thin skin in this region precludes most attempts at reestablishing this critical anatomic boundary.
Mastectomy Flap Thickness.
Because the breast gland develops as an ectodermally-derived structure that invaginates inward, it is bounded by the superficial and deep layers of the superficial fascia of the abdominal wall. The superficial layer of this fascia, often referred to as the "breast capsule" is subtle, but definitely present. As such, there exists a relatively avascular anatomic plane separating the non-breast tissue bearing fatty layer of the skin from the underlying breast parenchyma. 171 Mastectomy skin flaps should be raised just superficial to this enveloping fascia of the breast, preserving the subcutaneous fat and its associated vascular plexus in order to ensure skin flap viability. Several studies have confirmed this anatomic plane to be adequate from an oncologic perspective; flaps thinner than this (i.e., dermal) have a much higher risk of ischemic necrosis. Cooper's ligaments attaching the breast parenchyma to dermis require division to remove the gland from the skin flap. 172 End hits and thermal burns to the undersurface of the breast skin should be avoided. A low-blend coagulation setting, in conjunction with meticulous surgical technique and atraumatic retraction of the skin flaps can be helpful to ensure viable skin flaps of appropriate thickness. Other surgeons favor sharp dissection preceded by epinephrine injection, as an alternative means of avoiding thermal injury to the undersurface of mastectomy flaps.
Pectoralis Fascia. For total submuscular implant reconstruction, the fascia of the pectoralis major, serratus anterior, external oblique, and rectus abdominis muscles should be preserved. 173 The gland can be removed whilst protecting the fascia of these muscles as the posterior surface of the breast parenchyma is enveloped by the deep layer of the superficial abdominal fascia, a layer which is distinct from the muscle fasciae. When using acellular dermal matrices, preservation of the fascia is not essential.
Inframammary Fold. The inframammary fold is a distinct embryological and anatomical landmark that marks the end of the breast inferiorly. The breast boundary is at the point where the superficial and deep layers of the superficial fascia of the abdominal wall come together. 174 Here the superficial fascia adheres to the underlying chest wall. 175 Preservation of the inframammary fold is essential to define ptosis and inferior quadrant shape. 175 
